January 2005 Archives
UAMS Sees Blood Stem-Cell Work Rise
The University of Arkansas for Medical Sciences performed 633 blood stem-cell transplants in 2004, a number that officials say rivals the top facility nationally for blood stem-cell transplants, M. D. Anderson Cancer Center in Houston.
...Continue reading "UAMS Sees Blood Stem-Cell Work Rise"
Posted on January 31, 2005 08:28 PM | Comments (2) | TrackBack
China Set to Become Stem Cell Research Leader
When Jianhong Zhu, professor of neurosurgery at the city's Fudan University's Huashan Hospital, treated a patient with a chopstick lodged in his brain, not an uncommon injury in China, the culinary implement ultimately helped repair the damage it had caused.
Pulling out the offending object, the Harvard-trained doctor saw fresh brain tissue and decided to culture it in the laboratory and transplant it into the patient.
It was the start of a breakthrough in treating nerve damage and a sign that China is set to become the leader in the field of stem cell research, a field that could in the future help ailments as diverse as paralysis and incontinence.
...Continue reading "China Set to Become Stem Cell Research Leader"
Posted on January 27, 2005 02:43 PM | Comments (0) | TrackBack
S.D. Still in the Running for Stem Cell HQs
News the other day were saying that several California cities (San Francisco, Sacramento, Los Angeles, San Diego and other) plan to offer incentives ranging from free rent to discounts on nearby hotel rooms in a bid to lure the state's new stem cell research headquarters.
Some business and biotech insiders originally thought it would be a slam-dunk for the San Francisco Bay Area to land the institute because the region is home to the world's biggest concentration of biotechnology companies. San Diego has also been considered a top contender.
...Continue reading "S.D. Still in the Running for Stem Cell HQs"
Posted on January 27, 2005 01:56 PM | Comments (0) | TrackBack
Stem Cell Research Debate In Texas
Scientists believe stem cell research could provide promising treatments and cures for everything from diabetes to cancer and heart disease.
The question is if and how Texas can help future stem cell research.
...Continue reading "Stem Cell Research Debate In Texas"
Posted on January 27, 2005 01:41 PM | Comments (0) | TrackBack
Indiana Joins Stem Cell Research Pursuit
EndGenitor Technologies, backed by angel investors and housed Downtown at the Indiana University Emerging Technologies Center incubator, plans to use stem cells from umbilical cords to repair blood vessels.
EndGenitor was founded by Drs. Mervin Yoder and David Ingram, Indiana University School of Medicine researchers who discovered the stem cells early last year.
...Continue reading "Indiana Joins Stem Cell Research Pursuit"
Posted on January 27, 2005 01:11 PM | Comments (0) | TrackBack
ReNeuron Comments on Research Highlighting Contamination of Certain Stem Cell Lines
ReNeuron, an UK-based stem cell research and development company, has noted the recent publication in Nature Medicine of findings by US researchers indicating that human embryonic stem cell lines (ESCs) have been contaminated by non-human molecules derived from the animal feeder cell layers used to grow the cells.
...Posted on January 27, 2005 12:54 PM | Comments (0) | TrackBack
Governor Appoints Dean to Stem-Cell Commission
Dr. Brian Henderson, dean of the Keck School of Medicine, has been appointed by Gov. Arnold Schwarzenegger as a member of the Independent Citizens Oversight Committee, a board formed to manage and oversee the allotment of $3 billion for stem-cell research.
...Continue reading "Governor Appoints Dean to Stem-Cell Commission"
Posted on January 27, 2005 12:22 PM | Comments (0) | TrackBack
Stem Cell Stocks Take a Beating
Yesterday was a rough day in the market for many stem cell related companies. More than half of the stem cell stocks we monitor had prices drop, and some as much as 11%.
Appears that the animal protein contamination issue is still hitting hard and still filtering down to some investors....
...Continue reading "Stem Cell Stocks Take a Beating"
Posted on January 27, 2005 12:02 PM | Comments (0) | TrackBack
Spleen May Be Source Of Stem Cells For Diabetes Treatment
A year ago, Massachusetts General Hospital (MGH) researchers discovered that the spleen might be a source of adult stem cells that could regenerate the insulin-producing islets of the pancreas. In a follow-up to that finding, members of the same team are now reporting that these potential stem cells could produce a protein previously believed to be present only during the embryonic development of mammals.
...Continue reading "Spleen May Be Source Of Stem Cells For Diabetes Treatment"
Posted on January 26, 2005 04:41 PM | Comments (0) | TrackBack
Stem Cell Therapy Improves Heart Failure Treatment
Patients with heart failure complications experienced a marked improvement after being given an injection of their own stem cells, investigators reported today at the Annual Meeting of the Society for Thoracic Surgery in Tampa, Florida.
...Continue reading "Stem Cell Therapy Improves Heart Failure Treatment"
Posted on January 26, 2005 11:11 AM | Comments (0) | TrackBack
Biologists Find Stem Cell Regulator
Duke University Medical Center cell biologists have defined a signaling system between stem cells and the specialized "niche cells" that harbor and regulate them.
The findings provide better understanding of the signals that stimulate stem cells to either create more copies of themselves or to differentiate into another cell type, said the researchers.
...Continue reading "Biologists Find Stem Cell Regulator"
Posted on January 26, 2005 10:51 AM | Comments (0) | TrackBack
In California Stem Cell Advocates Seek Research Freedom
Advocates of embryonic stem cell research urged the Bush administration Monday to loosen federal policy to allow new colonies of stem cells to be created with federal grant money.
A study released over the weekend confirmed the widely held assumption among scientists that the handful of older stem cell lines now eligible for federal research grants had taken up animal proteins, which almost certainly makes the cell lines unsuitable for use in human medicine.
...Continue reading "In California Stem Cell Advocates Seek Research Freedom"
Posted on January 26, 2005 10:17 AM | Comments (0) | TrackBack
Stem Cell Research Progress Regarding Diabetes
Several recent studies underline stem cell research as a basis for critically-needed therapies for type 1 diabetes. Insulin-producing cells have already been created using embryonic stem cells from mice as well as in preliminary studies using embryonic cell lines from humans. In addition, adult stem cells from mouse bone marrow have shown therapeutic potential in mice...
This is a breakdown of the findings thus far ...
...Continue reading "Stem Cell Research Progress Regarding Diabetes"
Posted on January 25, 2005 06:00 PM | Comments (0) | TrackBack
Bio-Matrix Applies for Membership in the Cryogenic Society of America
Bio-Matrix Scientific Group Inc. (Nasdaq: BMXG) has submitted its application for membership in The Cryogenic Society of America.
Bio-Matrix' President Brian Pockett stated, "In becoming a member of the Society, Bio-Matrix will strengthen its move towards the development of an Adult Stem Cell Cryogenic Bank."
...Continue reading "Bio-Matrix Applies for Membership in the Cryogenic Society of America"
Posted on January 25, 2005 04:58 PM | Comments (0) | TrackBack
ACT Appoints Mr. William Caldwell, IV as Chief Executive Officer
Concurrent with the initial closing of its Series A financing on December 31st, 2004, the Board of Directors of Advanced Cell Technology has appointed Mr. William Caldwell, IV as Chief Executive Officer of the Company.
The Board of Directors has also appointed Dr. Michael West as Chairman, President and Chief Scientific Officer of the Company.
...Continue reading "ACT Appoints Mr. William Caldwell, IV as Chief Executive Officer"
Posted on January 25, 2005 04:32 PM | Comments (0) | TrackBack
Bio-Matrix Retains Patent Attorney to Assist in Patent Filing
Bio-Matrix Scientific Group Inc. (BMXG) has retained a Patent Attorney to assist in preparing to file its first patent relating to stem cell instruments. Dr. Phil Watts, the Company's Director of Research and Development said, "I believe the Company has reached a significant milestone in designing its first set of stem cell related instruments. I am extremely excited that we are at the point of preparing to file patent applications."
...Continue reading "Bio-Matrix Retains Patent Attorney to Assist in Patent Filing"
Posted on January 25, 2005 04:10 PM | Comments (0) | TrackBack
RegenTec Gets Government Funding for Stem Cell Research Targetting Blindness
A spin-out company from the University of Nottingham has been awarded around £250,000 of Government funding to develop innovative stem cell therapies that could one day provide new treatments for patients suffering from illnesses including Parkinson’s disease and stroks and blindness.
Continue reading "RegenTec Gets Government Funding for Stem Cell Research Targetting Blindness"
Posted on January 25, 2005 02:03 PM | Comments (0) | TrackBack
Stem-cell Stocks Damaged by Study Showing Contamination
Shares of three stem cell-related companies fell sharply Monday after a study asserted the bulk of embryonic stem cells used for U.S. research are contaminated and may not be suitable to transplant into humans.
Shares of Aastrom Biosciences closed down nearly 20 percent at $3.23. StemCells Inc. meanwhile, fell almost 16 percent to $4.99, and Geron Corp. lost 6.29 percent to $8.04. Shares of the newly public ViaCell Inc. appeared to be unscathed, moving up about 5.01 percent to $9.12.
...Continue reading "Stem-cell Stocks Damaged by Study Showing Contamination"
Posted on January 25, 2005 09:55 AM | Comments (0) | TrackBack
Pluristem Life Systems, Inc. (PLRS) Corp. Sheet
Corporate Summary (site quote):
Pluristem Ltd. was founded by Dr. Shai Meretzki and others following five years of research and development at the Technion Israel Institute of Technology in cooperation with the Weizmann Institute of Science. The Company has developed a unique technology for the expansion of stem cells, T-cells, and other blood-related cells.
...Continue reading "Pluristem Life Systems, Inc. (PLRS) Corp. Sheet"
Posted on January 24, 2005 06:38 PM | Comments (0)
Blair Backs City's £100m Fund for Stem-Cell Research
Sir Christopher Evans, Britain's leading biotechnology entrepreneur and the chairman of Merlin Biosciences, the venture capital group, is spearheading the plans to set up a public-private foundation to fund research into the area.
He has joined forces with Lord Winston, the fertility expert, Sir Richard Sykes, the rector of Imperial College and former chairman of GlaxoSmithKline, the pharmaceuticals group, and Jon Moulton of Alchemy Partners. Sir Richard Branson, the founder of Virgin, is also in talks to become a trustee....
...Continue reading " Blair Backs City's £100m Fund for Stem-Cell Research"
Posted on January 24, 2005 02:31 PM | Comments (0) | TrackBack
Stem Cell Treatment Reverses Diabetes
Millions of diabetics worldwide could put insulin injections behind them if a stem cell treatment that Argentine physicians have successfully used to reverse the disease confirms promising early results.
The treatment, in which stem cells are injected into the pancreas, does not involve risks of rejection, requires no prolonged inpatient treatment, and any physician trained in and skilled with catheterization could perform it, cardiologist Roberto Fernandez Vina told AFP....
...Continue reading "Stem Cell Treatment Reverses Diabetes"
Posted on January 24, 2005 02:13 PM | Comments (0) | TrackBack
California Stem Cell Agency Launches Website
California Institute for Regenerative Medicine, announced today the launch of its website (www.cirm.ca.gov).
The site will provide an interactive medium for the public to follow the activity and progress of the Institute as it works to support the development of disease cures and therapies through stem cell research....
...Continue reading "California Stem Cell Agency Launches Website"
Posted on January 24, 2005 01:55 PM | Comments (0) | TrackBack
Amgen Profits From Stem Cell IPO
ViaCell (nasdaq: VIAC), a Cambridge, Mass., biotech company developing therapies from umbilical cord stem cell, went public today, selling 7.5 million shares at an offering price of $7, at the bottom of its range.
...Continue reading "Amgen Profits From Stem Cell IPO"
Posted on January 24, 2005 12:22 PM | Comments (0) | TrackBack
Rell Announces $20 million for Stem Cell Research
Gov. M. Jodi Rell announced Friday that she wants to set aside $20 million of this year's estimated $316 million surplus to encourage stem cell research...
...Continue reading "Rell Announces $20 million for Stem Cell Research"
Posted on January 24, 2005 12:19 PM | Comments (0) | TrackBack
Embyonic Cell Lines in U.S. Too Contaminated to Use?
Based upon the strict policies of the U.S. government, entire batches of human embryonic stem cells which are available are contaminated with an animal molecule and are probably no good for using to treat people, scientists reported on Sunday....
...Continue reading "Embyonic Cell Lines in U.S. Too Contaminated to Use?"
Posted on January 24, 2005 09:43 AM | Comments (0) | TrackBack
Regenerating the Retina with Stem Cells
Amidst the estimated 1.5 million cells in the retina, it was found there is a relatively very small population of cells, about 10,000 cells per eye, that have retinal stem cell characteristics (proliferation, self-renewal, and multipotentiality)....
...Continue reading "Regenerating the Retina with Stem Cells"
Posted on January 21, 2005 10:18 PM | Comments (0) | TrackBack
Embryonic Stem Cell - Pluripotency
A new drug that activates the Wnt pathway maintains the undifferentiated state of pluripotent human and mouse embryonic stem cells. This finding opens the door to defining the precise molecular mechanism of embryonic stem cell self-renewal, which is crucial for providing a steady supply of embryonic stem cells for regenerative medicine.
Embryonic stem cells first emerged from the mouse embryonic inner cell mass into a petri dish in 1981, enabling the production of the first gene-targeted mouse in 1988.
Ten years later, the establishment of embryonic stem cells from human embryos turned attention to the development of embryonic stem cells for cell replacement therapy to treat diseases such as diabetes and Parkinson and Huntington diseases...
...Continue reading "Embryonic Stem Cell - Pluripotency"
Posted on January 21, 2005 09:48 PM | Comments (0) | TrackBack
AVI BioPharma gets stem-cell use patent
AVI BioPharma, Inc. (Nasdaq:AVII), today announced the issuance of United States Patent 6,841,542 B2, and notice of allowance on another patent, covering the use of antisense to modulate stem cell maturation.
AVI's third-generation NEUGENE(R) antisense agents, which target transforming growth factor beta (TGF-beta) and other gene targets, have been shown to program stem cells in culture for long-term survival after implantation....
...Continue reading "AVI BioPharma gets stem-cell use patent"
Posted on January 21, 2005 08:57 PM | Comments (0) | TrackBack
Stem Cell Research Discussed at Seminar
Recently, the ethics Committee of Northeast Hospital Corp. hosted a program at Beverly Hospital, "From Birth to Aging: The Implications for Stem Cell Research." Lecturers were: Curtis L. Cetrulo, MD, professor of obstetrics and gynecology at Tufts University School of Medicine, Boston; and Dennis J. Selkoe, MD, Vincent and Stella Coates Professor of Neurologic Diseases at Harvard Medical School and co-director at the Center for Neurologic Diseases at Brigham and Women's Hospital...
...Continue reading "Stem Cell Research Discussed at Seminar"
Posted on January 21, 2005 08:56 PM | Comments (0) | TrackBack
Good Results from Autologous Stem Cell Transplants for HIV Lymphomas
Researchers from the City of Hope Cancer Center have reported an 85% progression-free survival for 20 patients with HIV-related lymphoma treated with autologous stem cell transplants.
The results of this phase II clinical trial appeared in the January 15, 2005 issue of blood.
...Continue reading "Good Results from Autologous Stem Cell Transplants for HIV Lymphomas"
Posted on January 21, 2005 08:55 PM | Comments (0) | TrackBack
Clinical Trial Planned for Stem Cell Treatment for Stress Urinary Incontinence
ITL Laboratories, L.L.C. ("ITL") is planning a clinical trial to determine the effectiveness of a stem cell treatment for stress urinary incontinence.
A recent clinical trial by Austrian researchers has demonstrated the potential usefulness of expanded muscle stem cell injections in the treatment of urinary incontinence...
...Continue reading "Clinical Trial Planned for Stem Cell Treatment for Stress Urinary Incontinence"
Posted on January 21, 2005 08:49 PM | Comments (0) | TrackBack
Illinois House Republican Leader Tom Cross Promotes Embryonic Stem Cell Research for Diabetes
House Republican Leader Tom Cross of Oswego used last week's swearing-in ceremony to make an impassioned plea to his colleagues to establish a state fund for financing embryonic stem-cell research.
This is not merely a political stance, Cross. "This is a personal issue for me," said Cross, who introduced lawmakers to his 11-year-old daughter, Reynolds, who suffers from diabetes.
...Posted on January 21, 2005 08:47 PM | Comments (0) | TrackBack
Researchers in Russia Investigating Spinal Cord Treatment
Russian scientists modeled a severe spinal rupture within 60 test rats.
Stem cells in a polymer gel were injected into the region of the rupture for 24 rats; only polymer gel was injected with another group of rats and the third group was left intact without any operations ....
...Continue reading "Researchers in Russia Investigating Spinal Cord Treatment"
Posted on January 21, 2005 08:25 PM | Comments (0) | TrackBack
Stem Cell Therapy International, Corp. (SCII) Corp. Sheet
Corporate Summary (site quote):
Stem Cell Therapy International Corp. (SCTI), Tampa, FL, develops, manufactures, and distributes stem cell xeno-transplants (of animal origin) for medical treatment.
...Continue reading "Stem Cell Therapy International, Corp. (SCII) Corp. Sheet"
Posted on January 21, 2005 05:06 PM | Comments (0)
Genentech, Inc. (DNA) Corp. Sheet
Corporate Summary (site quote):
Genentech, the founder of the biotechnology industry, is a company with a quarter-century track record of delivering on the promise of biotechnology. Today, Genentech is among the world's leading biotech companies, with multiple protein-based products on the market for serious or life-threatening medical conditions and over 30 projects in the pipeline.
...Continue reading "Genentech, Inc. (DNA) Corp. Sheet"
Posted on January 21, 2005 04:31 PM | Comments (0)
LifeCell Corporation (LIFC) Corp. Sheet
Corporate Summary (site quote):
LifeCell is a leader in the development and commercialization of human-derived tissue based products for use in reconstructive, urogynecologic and orthopedic surgical procedures. The Company's patented technology produces a unique regenerative human tissue matrix—binding sites and vascular channels—that provides a complete template for the regeneration of normal human tissue. LifeCell's current products include: AlloDerm®, for plastic reconstructive, general surgical, burn and periodontal procedures; Cymetra®, a particulate form of AlloDerm suitable for injection; Repliform®, for urogynecologic surgical procedures; GraftJacket®, for orthopedic surgical procedures; and AlloCraft DBM, for bone grafting procedures.
...Continue reading "LifeCell Corporation (LIFC) Corp. Sheet"
Posted on January 21, 2005 04:17 PM | Comments (0)
ThermoGenesis Corp. (KOOL) Corp. Sheet
Corporate Summary (site quote):
ThermoGenesis Corp. is a leader in enabling technologies for cell therapeutics. The Company's technology platforms lead the world in their ability to produce biological products from single units of blood.
...Continue reading "ThermoGenesis Corp. (KOOL) Corp. Sheet"
Posted on January 21, 2005 03:54 PM | Comments (0)
Stem Cell Technology could Treat Cancer
New stem cell technology developed jointly by Cambridge and Japanese researchers to blitz killer cancers is to be commercialised by an American company.
Developed by Dr Toru Kondo, a neurobiologist at the Centre for Brain Repair at the University of Cambridge and colleagues from Kumamoto University, the technology separates cancer stem cells from cancer cell lines....
...Continue reading "Stem Cell Technology could Treat Cancer"
Posted on January 21, 2005 03:43 PM | Comments (0) | TrackBack
Bio-Matrix Scientific Group Attends the Stem Cell Conference
Bio-Matrix Scientific Group Inc. (BMXG) attended the Stem Cell Conference that represented the initial roll-out of Proposition 71, which was approved by California voters creating a $3 billion fund for stem cell research last November.
Bio-Matrix Scientific Group Inc. is a development stage company in the business of medical devices and monitoring systems research, development and commercialization. Bio-Matrix Scientific Group Inc. is aligning itself with partners that offer key technologies in biomedical device development, tissue engineering, cell culturing, genome therapy and drug delivery systems...
...Continue reading "Bio-Matrix Scientific Group Attends the Stem Cell Conference"
Posted on January 21, 2005 03:12 PM | Comments (0) | TrackBack
U.S. BioDefense, Inc. (UBDE) Corp. Sheet
Corporate Summary (site quote):
U.S. Biodefense is a high technology company that acquires, develops and finances Homeland Security related businesses and technologies for its own portfolio and those of its private and publicly traded corporate customers.
...Continue reading "U.S. BioDefense, Inc. (UBDE) Corp. Sheet"
Posted on January 21, 2005 03:10 PM | Comments (0)
AVI BioPharma (AVII) Corp. Sheet
Corporate Summary (site quote):
AVI is a biopharmaceutical company developing drugs to treat life-threatening diseases using third-generation antisense technology. We have completed eleven clinical trials with our NeuGene® antisense drugs in more than 300 subjects addressing cardiovascular restenosis, cancer, polycystic kidney disease and drug metabolism.
...Continue reading "AVI BioPharma (AVII) Corp. Sheet"
Posted on January 21, 2005 02:59 PM | Comments (0)
Cryo-Cell International, Inc. (CCEL) Corp. Sheet
Corporate Summary (site quote):
Incorporated in 1989, CRYO-CELL International, Inc. (OTCBB: CCEL) is the oldest and largest family cord blood stem cell bank in the United States. A pioneer in the industry, our primary focus is to provide a high quality, superior value service to expectant parents for the private collection, processing and cryopreservation of their newborn's U-Cord stem cells.
...Continue reading "Cryo-Cell International, Inc. (CCEL) Corp. Sheet"
Posted on January 21, 2005 02:43 PM | Comments (0)
Stem Cell Therapeutics, Corp. (SSS) Corp. Sheet
Corporate Summary (site quote):
Calgary-based Stem Cell Therapeutics Corp. (SCT) is a biotechnology company focused on the development of its technology platform and intellectual property to selectively induce a patient's own stem cells to proliferate in the brain.
...Continue reading "Stem Cell Therapeutics, Corp. (SSS) Corp. Sheet"
Posted on January 21, 2005 02:21 PM | Comments (0)
Mesoblast Limited (MSB) Corp. Sheet
Corporate Summary (site quote):
Mesoblast Limited is an Australian biotechnology company committed to the rapid development and commercialisation of therapies to treat patients with bone and joint diseases. Mesoblast is developing a proprietary adult stem cell technology for the treatment of orthopaedic conditions such as bone fractures and damaged or degenerated knee cartilage and vertebral discs. These conditions affect countless numbers of patients worldwide for whom no effective therapy exists today.
Continue reading "Mesoblast Limited (MSB) Corp. Sheet"
Posted on January 21, 2005 02:16 PM | Comments (0)
Bio-Matrix Scientific Group, Inc. (BMXP) Corp. Sheet
Corporate Summary (site quote):
Bio-Matrix Scientific Group (BMXP) is a Biotechnology Research and Development Company that is in the process of inventing, developing, acquiring, and subsequently, manufacturing and/or licensing intellectual properties for profit.
...Continue reading "Bio-Matrix Scientific Group, Inc. (BMXP) Corp. Sheet"
Posted on January 21, 2005 02:09 PM | Comments (0)
Genzyme Corporation (GENZ) Corp. Sheet
Corporate Summary (site quote):
Genzyme is one of the world's leading biotechnology companies. Its nearly 7,000 employees work in 30 countries and are united by a common goal: to make a major positive impact on the lives of people with debilitating diseases.
Continue reading "Genzyme Corporation (GENZ) Corp. Sheet"
Posted on January 21, 2005 02:06 PM | Comments (0)
MultiCell Technologies, Inc. (MUCL) Corp. Sheet
Corporate Summary (site quote):
MultiCell Technologies, Inc., is a leading provider of liver cell-based products for drug discovery and therapeutic applications. The Company specializes in innovative cell immortalization technologies that lead to the reproducible creation of highly functional cell lines.
...Continue reading "MultiCell Technologies, Inc. (MUCL) Corp. Sheet"
Posted on January 21, 2005 01:57 PM | Comments (0)
BrainStorm Cell Therapeutics, Inc. (BCLI.OB) Corp. Sheet
Corporate Summary (site quote):
BrainsStorm Cell Therapeutics LTD. is an Israeli subsidiary of BrainStorm Cell Therapeutics Inc., an emerging company developing neural-like cells derived from bone marrow for autologous brain transplantation in patients with neurodegenerative diseases, such as Parkinson's disease and Multiple Sclerosis.
...Continue reading "BrainStorm Cell Therapeutics, Inc. (BCLI.OB) Corp. Sheet"
Posted on January 21, 2005 01:52 PM | Comments (0)
ViaCell, Inc. (VIAC) Corp. Sheet
Corporate Summary (site quote):
The number of stem cells collected from any particular tissue source is typically low compared to the quantity required for therapeutic benefit. The likelihood and speed of successful stem cell engraftment are directly related to the number of stem cells transplanted. Consequently, the ideal approach to a successful transplant is to use a large number of stem cells. Researchers have been working for decades on methods for expanding populations of donated stem cells, but their efforts have been largely unsuccessful.
Continue reading "ViaCell, Inc. (VIAC) Corp. Sheet"
Posted on January 21, 2005 01:41 PM | Comments (0)
Curis, Inc. (CRIS) Corp. Sheet
Corporate Summary (site quote):
Curis is a therapeutic drug development company. The Company's technology focus is on regulatory pathways that control repair and regeneration. Curis product development involves using proteins or small molecules to modulate these pathways, for example, increasing the pathway signals when they are insufficient or decreasing them when they are excessive.
...Continue reading "Curis, Inc. (CRIS) Corp. Sheet"
Posted on January 21, 2005 01:40 PM | Comments (0)
PharmaFrontiers Corporation (PFTR) Corp. Sheet
Corporate Summary (site quote):
PharmaFrontiers is a commercialization driven biotechnology company that develops autologous cellular therapies for the treatment of multiple sclerosis, congestive heart failure, and diabetes. The company is focused on autologous cellular therapy applications based on its proprietary stem cell and T-cell vaccination technologies.
...Continue reading "PharmaFrontiers Corporation (PFTR) Corp. Sheet"
Posted on January 21, 2005 01:27 PM | Comments (0)
Osiris Therapeutics, Inc. Corp. Sheet
Corporate Summary (site quote):
Osiris Therapeutics is a clinical stage biotechnology company founded to commercialize stem cell products from a readily available and non-controversial source, adult bone marrow. These stem cells have the ability to repair different types of tissue and offer a very real opportunity to develop revolutionary new treatments for certain disease processes including immune disorders, heart attacks and arthritis.
Continue reading "Osiris Therapeutics, Inc. Corp. Sheet"
Posted on January 21, 2005 12:38 PM | Comments (0)
AnorMED, Inc. (AOM.TO) Corp. Sheet
Corporate Summary (site quote):
AnorMED was founded in 1996 and listed on the TSX as AOM in 1999. To date, the Company has raised over $130 million to support its research and development programs. Over the past seven years AnorMED has grown to over 100 employees - the majority of which are scientists - including chemists, biochemists and biologists.
...Continue reading "AnorMED, Inc. (AOM.TO) Corp. Sheet"
Posted on January 21, 2005 12:31 PM | Comments (0)
Stem Cell Research Targeting Hair Loss or Baldness
Interestingly enough, we see a good many queries here looking for news regardingly hair loss or male pattern balding. So I thought it might be good to dig a bit and see whats out there. Not suprising, there is quite a bit.
Just as stem cells are seen as possible treatment solutions for organ repair such as the heart and spinal cord, similar research involving our most widespread organ .. our skin .. has researchers looking at possible cosmetic applications.
From work done at hair loss clinics to research in purely biotech or biology labs, there is no shortage of information out there ..
...Continue reading "Stem Cell Research Targeting Hair Loss or Baldness"
Posted on January 21, 2005 12:21 PM | Comments (0) | TrackBack
Geron Corporation (GERN) Corp. Sheet
Corporate Summary (site quote):
Geron is focused on developing and commercializing therapeutic and diagnostic products for cancer based on their telomerase technology, and cell-based therapeutics using their human embryonic stem cell technology.
...Continue reading "Geron Corporation (GERN) Corp. Sheet"
Posted on January 21, 2005 12:21 PM | Comments (0)
Advanced Cell Technology, Inc. (ACTC) Corp. Sheet
Corporate Summary (site quote):
Advanced Cell Technology, Inc. is the leading biotechnology company in the emerging field of regenerative medicine.
...Continue reading "Advanced Cell Technology, Inc. (ACTC) Corp. Sheet"
Posted on January 21, 2005 11:55 AM | Comments (0)
Aastrom Biosciences, Inc. (ASTM) Corp Sheet
Aastrom Biosciences, Inc. develops proprietary patient-specific cell therapeutics for stem cell tissue repair, and the treatment of cancer and infectious disease.
...Continue reading "Aastrom Biosciences, Inc. (ASTM) Corp Sheet"
Posted on January 21, 2005 11:20 AM | Comments (0)
More on U.S. State Level Stem Cell Funding
Current State level developments in the funding of stem cell research is still moving forward at a rapid pace:
New York state Sen. David Paterson, a Democrat, introduced legislation last weekend that, if approved by voters, would dedicate $1 billion in public funding to the controversial research over the next 10 years.
New Jersey acting Gov. Richard Codey last week asked voters to commit $380 million in public funds for stem cell research. That includes $150 million of already-approved capital funds for the New Jersey Stem Cell Institute; Codey hopes voters will OK another $230 million in bonds this fall......
...Continue reading "More on U.S. State Level Stem Cell Funding"
Posted on January 20, 2005 11:56 AM | Comments (0) | TrackBack
Nebraska Lawmakers Debate Stem Cell and Cloning Legislation
Fearing that a legislative attempt to ban human cloning will undermine medical research, a Nebraska lawmaker is offering a bill that would ensure that stem-cell research is allowed to continue in the state...
Essentially what we are looking at in this, though with a twist, is still the embyonic stem cell debate combined with a cloning debate....
...Continue reading "Nebraska Lawmakers Debate Stem Cell and Cloning Legislation"
Posted on January 20, 2005 11:44 AM | Comments (0) | TrackBack
California Stem Cell Initiative Draws 60 Participants
There has been a forum on stem cell research yesterday held at the Salk Institute in La Jolla, by the California Research and Cures Coalition, a nonprofit group that advocates stem cell research.
The forum was part of an effort to answer taxpayers' questions about the stem cell bond (Proposition 71) initiative voters approved in November...
...Continue reading "California Stem Cell Initiative Draws 60 Participants"
Posted on January 20, 2005 11:26 AM | Comments (0) | TrackBack
CA. Proposition 71 Directors Disclose Personal Holdings Data
Directors of California's $3 billion stem cell venture revealed an array of financial holdings Tuesday, including some ties with biomedical companies, but